Difference between revisions of "Schmidt M, et al. Ann. Oncol. (2010) cited as Ref 564 in DOI: 10.1038/s41392-020-0110-5 (Q9827)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 21, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: Page(s) (P105): 275-282, #quickstatements; #temporary_batch_1590074839150) |
||
| (One intermediate revision by the same user not shown) | |||
| Property / title | |||
| + | An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer (English) | ||
| Property / title: An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 275-282 | ||
| Property / Page(s): 275-282 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Schmidt M, et al. Ann. Oncol. (2010) cited as Ref 564 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Schmidt M
0 references
2010
0 references
Ann. Oncol.
0 references
21
0 references
An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer (English)
0 references
275-282
0 references
